Navigating the hidden complexity of cloud-connected medical devices
MedTech consultancy TTP explores the engineering challenges behind developing secure, reliable and clinically valuable cloud-connected medical device ecosystems.
Engineering lessons from eight years of scalable ultrasound development
Medtech consultancy TTP PLC explores the engineering lessons behind eight years of developing a scalable software-defined ultrasound platform.
Bridging Cambridge’s MedTech scale-up gap: the missing link between prototype and production
Cambridge leads in early-stage MedTech innovation, but many promising ideas stall when moving from lab prototypes to clinical-ready devices. The core challenge lies in fragmented, early-stage manufacturing and regulatory pathways, often pushing companies to look overseas. This reflects a broader UK gap in scaling MedTech innovation.
The retinal delivery bottleneck: why today’s tools won’t scale
Cell and gene therapies make up a large and growing proportion of pipeline treatments for high-prevalence diseases of the retina. For these advanced therapies to deliver on their promise, most need to be delivered into the retina, overcoming significant physiological barriers. But existing retinal delivery is a slow, skilled, small-scale business: enabling patients with high-prevalence diseases…
Regulatory compliance in medical device development: a driver for success
Treating regulatory compliance as a late-stage hurdle creates risk, redesigns, and delays, especially for complex wearable and implantable devices. Bringing regulatory thinking in early turns compliance into a design tool, reducing uncertainty and helping teams move faster with confidence. TTP's latest guide on regulatory compliance in medical device development explains how to integrate…
TTP releases new e-book on closing the loop in neuromodulation therapy
TTP has released a new e-book exploring how closed-loop neuromodulation systems can deliver more personalised, responsive therapies. It examines the role of clinically meaningful biomarkers, algorithms, and system-level design in turning real-time sensing into reliable treatment. The e-book draws on TTP’s neurotechnology expertise to help teams de-risk development and accelerate next-generation…
TTP improves Bluetooth connectivity for implantable continuous glucose monitors
TTP’s Biosensing team has tackled one of the biggest challenges in implantable continuous glucose monitors: achieving reliable Bluetooth® Low Energy (BLE) connectivity within extreme size and power constraints. By taking a system-level approach that integrates RF design, antenna miniaturisation, and real-world testing, the team has demonstrated how dependable wireless performance can be achieved…
TTP Plc extends ISO 13485 certification to contract manufacture of medical devices and IVDs
TTP plc has expanded its ISO 13485 certification to include the contract manufacture of medical devices and in vitro diagnostics, covering implantable and active implantable devices. This extension builds on TTP’s 15-year track record in ISO-certified medical device development and reinforces its ability to support clients in bringing advanced technologies to market. By keeping manufacturing in…
An industry agenda for advanced therapies
11 priorities for building scalable and accessible advanced therapies.
Invent: Life Sciences podcast - make way for advanced therapies – why manufacturing could be coming to a hospital near you
Season 3, Episode 6. In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.
Invent: Life Sciences podcast - Automation, Access, and the Future of Manufacturing
Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible.
STEMCELL Technologies announces acquisition of Cellular Highways
Vancouver, British Columbia and Cambridge, United Kingdom, June 02, 2025 – STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene…
Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing
Companies to develop integration strategies for Fresenius Kabi’s portfolio of Cell Therapy Technologies within Cellular Origins’ Constellation automation platform Initial research to focus on integration of the Cue® Cell Processing System for automated sma
TTP Campus in Cambridgeshire named UK's most outstanding workplace
British Council for offices crowns the UK's best workplaces.
Cellular Origins, a TTP Company, appoints Peter Crossley as Chief Operating Officer
Product and technology innovator will build team to further develop and deliver Cellular Origins’ products for cell and gene therapy manufacture at scaleCAMBRIDGE, UK - Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and e
Cellular Origins, a TTP Company, establishes Advisory Board of global industry leaders
Renowned experts from across the CGT and robotics industries, Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge appointed to provide strategic and technical perspectives
TTP are moving to their all-new ‘TTP Campus’ in April
The Technology Partnership (TTP) are getting ready to move into a new technology campus, a fantastic bespoke facility designed with a clear vision, to create a premium space which can support our people and our clients as we develop and deliver the very best technology solutions.
TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies
TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies.
The Lee Company Inc. acquires TTP Ventus Limited
WESTBROOK, Connecticut (USA) - The Lee Company is pleased to announce that it has acquired TTP Ventus Limited from TTP Group.
TTP and Ionomr Innovations demonstrate low cost technology to enable scale-up of green hydrogen electrolysers
TTP, Europe’s leading technology and product development company, and Ionomr Innovations Inc., designer and manufacturer of next generation ion-exchange membranes and polymers for clean energy, announces they are joining forces to demonstrate a new green hydrogen electrolyser designed for mass production.
Omnispace teams with TTP to expand 5G development partner ecosystem
Omnispace, the company redefining mobile connectivity for the 21st century, announces that it is teaming up with TTP, an independent technology and product development company based in the UK. Omnispace is assembling a world-class team of partners as it makes 5G non-terrestrial networks (NTN) a reality. TTP will play an integral role in the development of the Omnispace global 5G hybrid…
TTP opens dedicated new manufacturing space at Cambridge HQ
TTP plc, a leading independent UK technology and product development company, has announced the opening of a brand new dedicated manufacturing facility at its HQ in Cambridge.
Bruntwood SciTech expands into golden triangle with acquisition of Melbourn Science Park in Cambridge
Bruntwood SciTech - the 50:50 joint venture between Bruntwood and Legal & General - announces its expansion into the ‘Golden Triangle’ through the acquisition of Melbourn Science Park in Cambridge, growing its national network of innovation districts and forming a new strategic partnership with leading independent technology and product development company TTP plc (TTP).
TTP extends respiratory product offering with innovative new asthma and COPD inhaler
TTP has partnered with Hovione Technology and H&T Presspart to design a new respiratory device; the PowdAir® Plus Dry Powder Inhaler (DPI).
TTP developing new COVID-19 screening technology to be used by 'anyone, anywhere'
The Technology Partnership Plc (TTP), a leading independent technology and product development company, is seeking go-to-market partnerships for CoTest™, a new pooled screening technology for Covid-19.